Cell viability results from KPC BRCA2-proficient murine pancreatic tumor cells and BRCA2-deficient KPB tumor cells confirmed higher cytotoxicity of Niraparib in pancreatic cancer regardless of BRCA status (Figure S1). The gene discussed is BRCA2; the disease is pancreatic neoplasm.